Global Women's Health Market 2017-2023

  • ID: 4413934
  • Report
  • Region: Global
  • 353 pages
  • BIS Research
1 of 5
Global Women’s Health Market to reach $42.12 Billion by 2023

FEATURED COMPANIES

  • Abbott Laboratories
  • Amgen Inc.
  • Eli Lilly and Company
  • FERRING PHARMACEUTICALS
  • HRA Pharma
  • Novo Nordisk
  • MORE

The world population is constantly increasing & was estimated to be approximately 7.5 billion in April 2017. Women accounted for 49.6% of the total world population. They form an important part of the society and hence, the concerns regarding women’s health are pivotal for the overall well-being of the society. Women have higher life expectancy than men but a longer life does not ensure a healthy life.

Women health has long been a neglected issue, worldwide. Women undergo several biological, physical & psychological changes during their lifetime. These reoccurring changes, along with ageing, consequently lead to several health issues and related problems.  The world population is ageing faster and women accounted for 54% of the population belonging to the age group of 60 years or over, in 2015. This percentage is expected to increase in the coming years. The different health issues that women face include infertility, hormonal changes, postmenopausal disorders and urinary infections, among others. The use of contraceptives by women is another issue that needs to be addressed. The market analysis includes an in-depth examination of the key ecosystem players and the key strategies & developments taking place in this market. Additionally, it includes the market dynamics (market drivers, opportunities and challenges) and industry analysis.

The purpose of the study is to gain a holistic view of the women’s health market in terms of the various factors influencing it, such as recent trends, technological advancements, and regulatory aspects of the market. The scope of this report is centred upon conducting a detailed study of the solutions allied with the women’s health market. The market has been segmented into ‘application’, ‘product’ and ‘geographical regions’. The report presents the reader with an opportunity to unlock the comprehensive insights with respect to the market and helps in forming well informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.

This research report aims at answering various aspects of the global women’s health market with the help of the key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The study considers the growth-share matrix model for a comprehensive study of the global women’s health market and assesses the factors governing the same.

The answers to the following key questions can be derived from this report:

  • What are the major market drivers, challenges and opportunities in the global women’s health market?
  • How did the women’s health market evolve in the past and what is its scope in the future?
  • What is the market share of the leading segments and sub-segments of the global women’s health market in 2016 and 2023?
  • How will each segment of the global women’s health market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2023?
  • What are the influencing factors that may affect the market share of the key players?
  • How will the industry evolve during the forecast period 2016- 2023?
  • What are the key developmental strategies that are being implemented by the key players to stand out in this market?
  • How the market has been segmented on the basis of application?
  • What are the treatment options for postmenopausal symptoms?
  • What is the estimated value for menopausal hot flash market?
  • What is the value of different types of contraceptives in the market?
  • What will be the value of hormonal contraceptives segment by 2023?
  • Which geographical location will contribute to the highest sales of the products?

The key players which have been significantly contributing to the Women’s health market are Neurocrine Biosciences, Gedeon Richter Plc, Ferring Pharmaceuticals, enteris BIOPHARMA, Bayer Healthcare,  F. Hoffmann-La Roche AG, Pfizer Inc., Novo Nordisk, Allergan, Plc, Radius Health Inc., Agile THERAPEUTICS, Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals, Vertical Pharmaceuticals, and Veru HEALTHCARE, among others.

READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Amgen Inc.
  • Eli Lilly and Company
  • FERRING PHARMACEUTICALS
  • HRA Pharma
  • Novo Nordisk
  • MORE

Executive Summary                           

1    Report Scope                       
1.1    Scope of the Report                   
1.2     Global Women's Health Market Segmentation
1.3    Key Learnings                   
1.4    Research Methodology                   
1.4.1.    Data Triangulation               
1.4.2.    Key Data Points From Secondary Sources                
1.4.3.    Key Data Points From Primary Sources                
1.4.4.     Top-Down  Approach (Segmental Analysis)
1.4.5.     Bottom-Up Approach (Segmental Analysis)
1.4.6.     Assumptions and Limitations
1.4.7.     Data and Prediction Modelling

2    Market Overview                       
2.1    Introduction                   

3    Market Dynamics                       
3.1.    Market Drivers                   
3.2.    Market Challenges                   
3.3.    Market Opportunities                   

4    Competitive Insights                       
4.1.    Share of Key Developments & Strategies                   
4.1.1.     Collaborations/ Partnerships/ Joint Ventures/ Licensing Agreements
4.1.2.    Regulatory Approvals               
4.1.3.    Mergers and Acquisitions               
4.1.4.    Business Expansions and Product Acquisitions               
4.1.5.     Product Launches
4.1.6.    Others               

5    Industry Insights                       
5.1.    Regulatory Scenario                   
5.2.    Patent Landscape                   

6    Global Women's Health Market, by Application                       
6.1.    Segmentation of Global Women's Health Market, by Application                   
6.2.    Reproductive Health                   
6.2.1.    Infertility               
6.2.2.    Endometriosis               
6.2.3.    Poly Cystic Ovarian Syndrome (PCOS)               
6.2.4.    Contraceptives               
6.2.4.1.    Method of Contraceptive And Effectiveness           
6.2.4.2.    Types of Contraceptives           
6.3.    Post Menopausal Health                   
6.3.1.    Menopause               
6.3.2.    Post Menopausal Osteoporosis               
6.4.    Urological Disorders                   
6.4.1.    Urinary Incontinence               
6.4.2.    Urinary Tract Infection               
6.4.3.    Others               

7    Global Women's Health Market, by Product Type                       
7.1.    Introduction                   
7.2.     Devices                   
7.2.1.    Intra Uterine Devices               
7.2.2.    Vaginal Rings               
7.2.3    Implants               
7.2.4.    Female Condoms               
7.3.    Drugs                   
7.3.1.    Drugs for Treatment of Menopause               
7.3.2.    Drugs for Treatment of Menopausal Hot Flashes                
7.4.    Pharmaceutical Pipeline                   

8    Global Women's Health Market, by Geography                       
8.1.    Introduction                   
8.2.    North America                   
8.3.    Europe                   
8.4.    Asia Pacific                   
8.5.    Rest of the World                   

9    Company Profiles                       
9.1.     Abbott Laboratories                   
9.1.1.    Overview               
9.1.2.    Abbott Laboratories: Product Portfolio               
9.1.3.    Financials               
9.1.3.1.    Financial Summary           
9.1.4.    Abbott Laboratories: SWOT Analysis               
9.2.    AGILE THERAPEUTICS                   
9.2.1.    Overview               
9.2.2.    AGILE THERAPEUTICS: Product Portfolio               
9.2.3.    Financials               
9.2.3.1.    Financial Summary           
9.2.4.    AGILE THERAPEUTICS: SWOT Analysis               
9.3.     Allergan plc.                   
9.3.1.    Overview               
9.3.2.    Allergan plc: Product Portfolio               
9.3.3.    Financials               
9.3.4.    Allergan plc.: SWOT Analysis               
9.4.     Amgen Inc.                   
9.4.1.    Overview               
9.4.2.     Amgen Inc.: Product Portfolio
9.4.3.    Financials               
9.4.3.1    Financial Summary           
9.4.4.    Amgen Inc.: SWOT Analysis               
9.5.    AstraZeneca PLC                   
9.5.1.    Overview               
9.5.2     AstraZeneca PLC: Product Portfolio
9.5.3.    Financials               
9.5.3.1.    Financial Summary           
9.5.4.     AstraZeneca PLC: SWOT Analysis
9.6.    Bayer AG                   
9.6.1.    Overview               
9.6.2.    Bayer AG: Product Portfolio               
9.6.3.    Financials               
9.6.3.1.    Financial Summary           
9.6.4.     Bayer AG: SWOT Analysis
9.7.    Eli Lilly and Company                   
9.7.1.    Overview               
9.7.2.    Eli Lilly and Company: Product Portfolio               
9.7.3.    Financials               
9.7.3.1.    Financial Summary           
9.7.4.     Eli Lilly and Company: SWOT Analysis
9.8.    Enteris BIOPHARMA, Inc                   
9.8.1.    Overview               
9.8.2.     Enteris BIOPHARMA, Inc: Product Portfolio
9.8.3.    Corporate Summary               
9.8.4.    Enteris BIOPHARMA, Inc: SWOT Analysis               
9.9.    Evestra, Inc                   
9.9.1.    Overview               
9.9.2.    Evestra, Inc: Product Portfolio               
9.9.3.    Corporate Summary               
9.9.4.     Evestra, Inc: SWOT Analysis
9.10.    FERRING PHARMACEUTICALS                   
9.10.1.    Overview               
9.10.2.     FERRING PHARMACEUTICALS: Product Portfolio
9.10.3.    Corporate Summary               
9.10.4.     FERRING PHARMACEUTICALS: SWOT Analysis
9.11.    GEDEON RICHTER PLC                   
9.11.1.    Overview               
9.11.2.     GEDEON RICHTER PLC: Product Portfolio
9.11.3.    Financials               
9.11.3.1.    Financial Summary           
9.11.4.     GEDEON RICHTER PLC: SWOT Analysis
9.12.    GlaxoSmithKline Plc                   
9.12.1.    Overview               
9.12.2.     Glaxo: Product Portfolio
9.12.3.    Financials               
9.12.3.1.    Financial Summary           
9.12.4.     GlaxoSmithKline Plc: SWOT Analysis
9.13.    HRA Pharma                   
9.13.1.    Overview               
9.13.2.     HRA Pharma: Product Portfolio
9.13.3.    Corporate Summary               
9.13.4.     HRA Pharma: SWOT Analysis
9.14.    JDS THERAPEUTICS,LLC                   
9.14.1.    Overview               
9.14.2.     JDS THERAPEUTICS,LLC : Product Portfolio
9.14.3.    Corporate Summary               
9.14.4.     JDS THERAPEUTICS, LLC: SWOT Analysis
9.15.    NEUROCRINE BIOSCIENCES, INC.                   
9.15.1.    Overview               
9.15.2.     NEUROCRINE BIOSCIENCES, INC.: Product Portfolio
9.15.3.    Financials               
9.15.3.1.    Financial Summary           
9.15.4.    NEROCRINE BIOSCIENCES, INC.: SWOT Analysis               
9.16.    Novartis International AG                   
9.16.1.    Overview               
9.16.2.     Novartis International AG: Product Portfolio
9.16.3.    Financials               
9.16.3.1.    Financial Summary           
9.16.4.    Novartis International AG: SWOT Analysis               
9.17.    NOVEN Pharmaceuticals,Inc.                   
9.17.1.    Overview               
9.17.2.    Parent Company: Hisamitsu Pharmaceutical Co., Inc.: Overview               
9.17.3.    Hisamitsu Pharmaceutical Co., Inc.: Product Portfolio               
9.17.4.    Financials               
9.17.4.1.    Financial Summary           
9.17.5.    NOVEN Pharmaceuticals, Inc.: SWOT Analysis               
9.18.    Novo Nordisk                   
9.18.1.    Overview               
9.18.2.    Novo Nordisk: Product Portfolio               
9.18.3.    Financials               
9.18.3.1    Financial Summary           
9.18.4.     Novo Nordisk: SWOT Analysis
9.19.    Pfizer Inc.                   
9.19.1.    Overview               
9.19.2.     Pfizer Inc.: Product Portfolio
9.19.3.    Financials               
9.19.3.1.    Financial Summary           
9.19.4.     Pfizer Inc.: SWOT Analysis
9.20.    Radius Health Inc.                   
9.20.1.    Overview               
9.20.2.     Radius Health Inc.: Product Portfolio
9.20.3.    Financials               
9.20.3.1.    Financial Summary           
9.20.4.     Radius Health Inc.: SWOT Analysis
9.21.    Teva Pharmaceuticals Industries Limited                   
9.21.1.    Overview               
9.21.2.     Teva Pharmaceuticals Industries Limited: Product Portfolio
9.21.3.    Financials               
9.21.3.1.    Financial Summary           
9.21.4.     Teva Pharmaceuticals Industries Limited: SWOT Analysis
9.22.    TherapeuticsMD, Inc.                   
9.22.1.    Overview               
9.22.2.     TherapeuticsMD, Inc.: Product Portfolio
9.22.3.    Financials               
9.22.3.1.    Financial Summary           
9.22.4.     TherapeuticsMD, Inc.: SWOT Analysis
9.23.    VALEANT PHARMACEUTICALS INTERNATIONAL Inc.                   
9.23.1.    Overview               
9.23.2.    VALEANT PHARMACEUTICALS INTERNATIONAL Inc.: Product Portfolio               
9.23.3.    Financials               
9.23.3.1.    Financial Summary           
9.23.4.     Valeant Pharmaceuticals International Inc.: SWOT Analysis
9.24.    VERTICAL PHARMACEUTICALS,LLC                   
9.24.1.    Overview               
9.24.2.    Parent Company: Osmotica Pharmaceuticals: Overview               
9.24.3.    VERTICAL PHARMACEUTICALS,LLC: Product Portfolio               
9.24.4.    Corporate Summary               
9.24.4.     VERTICAL PHARMACEUTICALS, LLC: SWOT Analysis
9.25.    VERU HEALTHCARE                   
9.25.1.    Overview               
9.25.2.     VERU HEALTHCARE: Product Portfolio
9.25.3.    Financials               
9.25.3.1.    Financial Summary           
9.25.4.     VERU HEALTHCARE: SWOT Analysis

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abbott Laboratories
  • AGILE THERAPEUTICS
  • Allergan plc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Eli Lilly and Company
  • Enteris BIOPHARMA, Inc
  • Evestra, Inc
  • FERRING PHARMACEUTICALS
  • GEDEON RICHTER PLC
  • GlaxoSmithKline Plc
  • HRA Pharma
  • JDS THERAPEUTICS,LLC
  • NEUROCRINE BIOSCIENCES, INC.
  • NOVEN PHARMACEUTICALS,Inc.
  • Novartis International AG
  • Novo Nordisk
  • Pfizer Inc.
  • Radius Health Inc.
  • Teva Pharmaceuticals Industries Limited
  • TherapeuticsMD, Inc.
  • VALEANT PHARMACEUTICALS INTERNATIONAL Inc.
  • VERTICAL PHARMACEUTICALS,LLC
  • VERU HEALTHCARE
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll